Patents Assigned to Novartis AG
  • Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
    Patent number: 11708366
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: July 25, 2023
    Assignee: Novartis AG
    Inventors: Mallesh Bushaboina, Xin Chen, Atwood Kim Cheung, Andrew James Culshaw, Timothy Brian Hurley, Nancy Labbe-Giguere, Wolfgang Miltz, David Orain, Tajesh Patel, Srinivasan Rajagopalan, Till Roehn, David Andrew Sandham, Gebhard Thoma, Ritesh Bhanudasji Tichkule, Rudolf Wälchli
  • Methods for treating hematologic cancers
    Patent number: 11708412
    Abstract: The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA4.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: July 25, 2023
    Assignees: Novartis AG, The Medical College of Wisconsin, Inc.
    Inventors: Bryon Duane Johnson, Robert Millman
  • Pyrazolyl derivatives useful as anti-cancer agents
    Patent number: 11702409
    Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: July 18, 2023
    Assignee: NOVARTIS AG
    Inventors: Simona Cotesta, Marc Gerspacher, Catherine Leblanc, Edwige Liliane Jeanne Lorthiois, Bo Liu, Rainer Machauer, Robert Mah, Christophe Mura, Pascal Rigollier, Nadine Schneider, Stefan Stutz, Andrea Vaupel, Nicolas Warin, Rainer Wilcken
  • FGF21 mimetic antibodies and uses thereof
    Patent number: 11692046
    Abstract: The present disclosure relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human ?-klotho, and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: July 4, 2023
    Assignee: Novartis AG
    Inventors: Regis Cebe, Stephane Olland, David Langdon Yowe
  • Engineered heterodimeric proteins
    Patent number: 11685776
    Abstract: The present invention provides heterodimeric antibodies and fragments thereof and methods for their preparation, wherein the pairing of heavy and light chains has been improved. Interface residues were mutated such that each light chain strongly favoured its cognate heavy chain when two different heavy chains and two different light chains were co-transfected and co-expressed in the same cell to assemble a functional, heterodimeric antibody or fragment thereof.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: June 27, 2023
    Assignee: Novartis AG
    Inventors: Regis Cebe, Sebastien Irigaray, Darko Skegro
  • Multi-dose ocular fluid delivery system
    Patent number: 11679028
    Abstract: Multi-dose ocular fluid delivery devices are provided. Aspects of the fluid delivery devices include a fluid package and an actuator. The fluid package includes a reservoir of an ophthalmic formulation, an aperture and a valve member for sealing the aperture when fluid is not being ejected therethrough. The actuator is configured to operate the valve member so as to at least reduce, if not prevent, ingress of outside materials or contaminants into the reservoir, such that the ophthalmic formulation present in the reservoir does not require a preservative (e.g., where a preservative-free ophthalmic formulation is present in the reservoir). Also provided are methods of using the devices in fluid delivery applications, as well as a kit that includes components of the devices.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: June 20, 2023
    Assignee: Novartis AG
    Inventors: Reynaldo Quintana, Yehuda Ivri
  • Carboxamide derivatives
    Patent number: 11672782
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: June 13, 2023
    Assignee: NOVARTIS AG
    Inventors: Kamlesh Jagdis Bala, Andrew Brearley, James Dale, Anne-Marie Edwards, Mahbub Ahmed, David Porter, Robert Alexander Pulz, Lisa Ann Rooney, David Andrew Sandham, Duncan Shaw, Nichola Smith, Jessica Louise Taylor, Roger John Taylor, Thomas Josef Troxler, Joe Wrigglesworth
  • 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions
    Patent number: 11672799
    Abstract: The present invention provides a compound of formula IA or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: June 13, 2023
    Assignee: NOVARTIS AG
    Inventors: Atwood Kim Cheung, Natalie Dales, Timothy Brian Hurley
  • Amino pyrimidine derivatives
    Patent number: 11673868
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Grant
    Filed: October 22, 2021
    Date of Patent: June 13, 2023
    Assignee: Novartis AG
    Inventors: Daniela Angst, François Gessier, Anna Vulpetti
  • Antiviral pyrazolopyridinone compounds
    Patent number: 11667613
    Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: June 6, 2023
    Assignees: Novartis AG, Gilead Sciences, Inc.
    Inventors: Zef Konst, Yipin Lu, Robert Joseph Moreau, Naomi Samadara Rajapaksa, Galen Shearn-Nance, David Charles Tully, Michael Robert Turner, Joseph Michael Young, Qian Zhao, Britton K. Corkey, Samuel E. Metobo
  • Treatment of cancer using chimeric CD3 receptor proteins
    Patent number: 11667691
    Abstract: The present disclosure features the use of chimeric CD3 proteins to modulate T cell Receptor (TCR) signaling. Specifically, the disclosure is based, in part, on the discovery that chimeric CD3 proteins (e.g., CD3delta, CD3gamma, and CD3epsilon) having all or most of their extracellular domain fused to an antigen binding domain can activate the TCR in the presence of a cognate antigen. The disclosure is further based on the observation that the above chimeric proteins can be potentiated through the inclusion of a co-stimulatory domain in the intracellular portion of the chimeric molecule. Thus, the preferred elements of the engineered signaling complexes of the disclosure include an antigen binding domain, an extracellular domain derived from one of the above CD3 proteins, and an intracellular co-stimulatory domain.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: June 6, 2023
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Andreas Loew, Brian Granda, Melissa Ramones
  • Crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1- yl)pyrimidin-4-amine and new salts
    Patent number: 11654144
    Abstract: This application relates to various crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine and salt thereof, as well as compositions and methods of using the same. In some embodiments the crystalline forms also contain water (“hydrates”). These materials are useful in the treatment of various diseases, including carcinomas, specifically lung cancer and more specifically non-small cell lung cancer.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: May 23, 2023
    Assignees: Novartis AG, Palobiofarma S.L.
    Inventors: Kai Cui, Julio Cesar Castro-Palomino Laria, Weiyong Kong
  • OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG
    Publication number: 20230151106
    Abstract: Ofatumumab may be used in treating multiple sclerosis (MS), wherein the treatment is a long-term treatment and wherein serum IgG level is maintained during the treatment. B cell and/or T cell inhibitors may be used in the treatment of MS, which treatment includes monitoring serum IgG level and selecting ofatumumab as the B cell and/or T cell inhibitor if the serum IgG level decreases and/or the treatment includes assessing the predisposition of the patient for an increased risk of infections and selecting ofatumumab as the B cell and/or T cell inhibitor if a predisposition is identified. Ofatumumab may be used in treating multiple sclerosis, wherein patients having a lowered serum IgG level are treated and/or wherein patients having risk factors associated with serum Ig levels, in particular serum IgG levels, are treated.
    Type: Application
    Filed: April 9, 2021
    Publication date: May 18, 2023
    Applicant: NOVARTIS AG
    Inventors: Ratnakar PINGILI, Martin MERSCHHEMKE
  • Thienopyrimidinone NMDA receptor modulators and uses thereof
    Patent number: 11648253
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: May 16, 2023
    Assignee: Novartis AG
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Method for preparing a pharmaceutical product
    Patent number: 11642315
    Abstract: A method of preparing a pharmaceutical product comprises the steps of (a) providing a neat active pharmaceutical ingredient (API) complying with at least five of the following parameters determined by using a FT4 powder rheometer: (i) specific basic flow energy of at most 60 mJ/g; (ii) stability index of 0.75 to 1.25; (iii) specific energy of at most 10 mJ/g; (iv) major principle stress at 15 kPa of at most 40; (v) flow function at 15 kPa of at least 1.3; (vi) consolidated bulk density at 15 kPa of at least 0.26 g/mL; (vii) compressibility of at most 47%; and (viii) wall friction angle of at most 40°; (b) dispensing the neat API of step (a) into a bottom part of a pharmaceutical carrier using a vacuum assisted metering and filling device; and (c) encapsulating the bottom part, thereby producing a pharmaceutical product.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: May 9, 2023
    Assignee: Novartis AG
    Inventors: Elodia Di Renzo, David Hook, Markus Krumme, Steffen Lang, Massimo Moratto, Joerg Ogorka, Jim Parks, Dale Ploeger, Norbert Rasenack, Hendrik Schneider, Stefan Steigmiller, Gordon Stout, Patrick Tritschler, Fabian Weber
  • Polyomavirus neutralizing antibodies
    Patent number: 11639378
    Abstract: The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: May 2, 2023
    Assignee: Novartis AG
    Inventors: Johanna Abend, Zorica Dragic, Adam Lloyd Feire, Mark Knapp, Steven Kovacs, Elisabetta Traggiai, Lichun Wang, Yongqiang Wang, Danqing Wu, Qilong Wu, Fangmin Xu
  • BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES
    Publication number: 20230128499
    Abstract: The present disclosure provides methods of treating a subject having a proliferative disease or an autoimmune disorder with a combination of (a) a first multispecific binding molecule (MBM) that binds specifically to (i) human CD2 and (ii) a human tumor-associated antigen and/or a human tumor microenvironment antigen, and (b) a second multispecific binding molecule that binds specifically to (i) a component of a human T-cell receptor (TCR) complex or a secondary T-cell signaling molecule and (ii) a human tumor-associated antigen and/or human tumor microenvironment antigen. The disclosure further provides MBMs and combinations of MBMs that can be used in the methods of the disclosure.
    Type: Application
    Filed: March 26, 2021
    Publication date: April 27, 2023
    Applicant: Novartis AG
    Inventors: Carl Uli BIALUCHA, Brian GRANDA
  • Anti-CCR7 antibody drug conjugates
    Patent number: 11634497
    Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: April 25, 2023
    Assignee: NOVARTIS AG
    Inventors: Steven Bender, Tracy Charlton, Anna Galkin, Bernhard Hubert Geierstanger, Scott Martin Glaser, Shailaja Kasibhatla, Mark Knuth, Sabine Rottmann, Sarah Rue, Glen Spraggon, Tetsuo Uno
  • 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1?,2?:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
    Patent number: 11629149
    Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: April 18, 2023
    Assignee: Novartis AG
    Inventors: Maxime Dauphinais, Rama Jain, Dennis Christofer Koester, James R. Manning, Vanessa Marx, Daniel Poon, Lifeng Wan, Xiaojing Michael Wang, Aregahegn Yifru, Qian Zhao
  • Solid forms comprising an oxime ether compound, compositions and methods of use thereof
    Patent number: 11629124
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: April 18, 2023
    Assignee: NOVARTIS AG
    Inventors: Lianfeng Huang, Daozhong Zou